Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar

Zydus Cadila gets USFDA’s nod for Ranolazine Extended-Release Tablets

21 Aug 2019

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Ranolazine Extended Release Tablets (US RLD- Ranexa), 500 mg and 1.000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group’s formulations manufacturing facility at Baddi.

The group now has 271 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003 -04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Related Cadila Healthcare Ltd. Links:

Cadila Healthcare Share Price

585.95 14.05 (2.46%) Jul 30, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 774.00
Dr. Reddy's Lab 4712.70
Lupin 1107.15
Cadila Healthcare 585.95
Aurobindo Pharma 916.85
View more..
Sensex vs Cadila Healthcare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback